Biogen (BIIB) is a publicly traded Healthcare sector company. As of July 20, 2026, BIIB trades at $205.05 with a market cap of $30.84B and a P/E ratio of 21.93. BIIB moved -1.39% today. Year to date, BIIB is +16.77%; over the trailing twelve months it is +60.07%. Its 52-week range spans $110.04 to $219.72. Analyst consensus is buy with an average price target of $222.67. Rallies surfaces BIIB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Biogen (BIIB) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. BIIB moved -1.39% today. Analyst consensus is buy.
| Metric | Value |
|---|---|
| Price | $205.05 |
| Market Cap | $30.84B |
| P/E Ratio | 21.93 |
| EPS | $9.35 |
| Dividend Yield | 0.00% |
| 52-Week High | $219.72 |
| 52-Week Low | $110.04 |
| Volume | 892.74K |
| Avg Volume | 0 |
| Revenue (TTM) | $9.94B |
| Net Income | $1.37B |
| Gross Margin | 75.49% |
28 analysts cover BIIB: 0 strong buy, 18 buy, 9 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $222.67.